Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antony Loebel

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
Current Medical Research and Opinion|April 8, 2018
Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychoticsDaisy Ng-Mak, Rachel Halpern, Krithika Rajagopalan, et al.
Schizophrenia Research|September 6, 2011
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSteven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, et al.
Schizophrenia Research|June 29, 2015
Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation studyPhilip D Harvey, Cynthia O Siu, Masaaki Ogasa, et al.
Schizophrenia Bulletin|October 6, 2017
Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With SchizophreniaSeth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
Journal of Medical Economics|June 8, 2013
Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-releaseKrithika Rajagopalan, Ken O'Day, Kellie Meyer, et al.
Schizophrenia Research|May 23, 2008
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disordersOfer Agid, Shitij Kapur, Lewis Warrington, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 20, 2013
Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the USKen O'Day, Krithika Rajagopalan, Kellie Meyer, et al.
Pharmacoeconomics|April 13, 2016
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with SchizophreniaKrithika Rajagopalan, David Trueman, Lydia Crowe, et al.
Psychiatry Research|November 23, 2020
Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)Seth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
CNS Spectrums|October 29, 2008
Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophreniaGeorge M Simpson, Cedric J O'Gorman, Antony Loebel, et al.
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
Current Medical Research and Opinion|April 8, 2018
Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychoticsDaisy Ng-Mak, Rachel Halpern, Krithika Rajagopalan, et al.
Schizophrenia Research|September 6, 2011
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorderSteven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, et al.
Schizophrenia Research|June 29, 2015
Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation studyPhilip D Harvey, Cynthia O Siu, Masaaki Ogasa, et al.
Schizophrenia Bulletin|October 6, 2017
Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With SchizophreniaSeth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
Journal of Medical Economics|June 8, 2013
Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-releaseKrithika Rajagopalan, Ken O'Day, Kellie Meyer, et al.
Schizophrenia Research|May 23, 2008
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disordersOfer Agid, Shitij Kapur, Lewis Warrington, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 20, 2013
Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the USKen O'Day, Krithika Rajagopalan, Kellie Meyer, et al.
Pharmacoeconomics|April 13, 2016
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with SchizophreniaKrithika Rajagopalan, David Trueman, Lydia Crowe, et al.
Psychiatry Research|November 23, 2020
Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)Seth C Hopkins, Ajay Ogirala, Antony Loebel, et al.
CNS Spectrums|October 29, 2008
Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophreniaGeorge M Simpson, Cedric J O'Gorman, Antony Loebel, et al.
Pageof 13